Therefore, this study applied a low-dose combination of LiCl and LY294002 to treat osteoporosis and to test whether this method can inhibit osteoclast activity and promote osteoblast activity through inhibition of the AKT/GSK3β/β-catenin/NFATC1 pathway. Here, NFATC1 is linked to osteoporosis.